Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, a growth of 23.6% from the November 30th total of 1,230,000 shares. Approximately 4.6% of the shares of the stock are sold short. Based on an average daily volume of 744,600 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Trading Down 2.0 %

Shares of HOWL stock traded down $0.03 on Tuesday, hitting $1.45. 205,872 shares of the company’s stock traded hands, compared to its average volume of 379,897. The stock has a market capitalization of $64.62 million, a price-to-earnings ratio of -0.95 and a beta of 0.30. The company’s fifty day simple moving average is $2.04 and its 200 day simple moving average is $2.20. Werewolf Therapeutics has a one year low of $1.38 and a one year high of $8.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $34,000. XTX Topco Ltd bought a new position in shares of Werewolf Therapeutics in the third quarter worth approximately $45,000. Rhumbline Advisers purchased a new position in shares of Werewolf Therapeutics in the second quarter worth $79,000. Finally, American Century Companies Inc. increased its stake in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after buying an additional 12,656 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.